Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMYDNQ2)

• Drug Name: CA102N Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMYDNQ2

Molecule-Related Drug Atlas

Drug(s) Targeting Prostaglandin G/H synthase 2 (COX-2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[3]
Naproxen	DMZ5RGV	Bursitis		Approved	[4]
Etodolac	DM6WJO9	Osteoarthritis	FA00-FA05	Approved	[5]
Indomethacin	DMSC4A7	Bursitis		Approved	[6]
Celecoxib	DM6LOQU	Dysmenorrhea	GA34.3	Approved	[7]
Nabumetone	DMAT2XH	Osteoarthritis	FA00-FA05	Approved	[8]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[9]
Flurbiprofen	DMGN4BY	Osteoarthritis	FA00-FA05	Approved	[10]
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Hypertriglyceridemia	5C80.1	Approved	[11]
Aminosalicylic Acid	DMENSL5	Crohn disease	DD70	Approved	[6]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Prostaglandin G/H synthase 2 (COX-2)	TTVKILB	PGH2_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT03616574) First-in-human Study of CA102N Monotherapy and of CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health.
• [2] National Cancer Institute Drug Dictionary (drug name CA102N).
• [3] Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development. Reprod Toxicol. 2009 Sep;28(2):239-44.
• [4] Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
• [5] Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. Intern Med. 2007;46(13):1055-8.
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [7] Pfizer. Product Development Pipeline. March 31 2009.
• [8] Renal effects of nabumetone, a COX-2 antagonist: impairment of function in isolated perfused rat kidneys contrasts with preserved renal function in vivo. Exp Nephrol. 2001;9(6):387-96.
• [9] Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
• [10] Flurbiprofen, a cyclooxygenase inhibitor, protects mice from hepatic ischemia/reperfusion injury by inhibiting GSK-3 signaling and mitochondrial permeability transition.Mol Med.2012 Sep 25;18:1128-35.
• [11] Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.